Meet with... Illumina

Mar 16 2017https://www.eventbrite.com/e/meet-with-illumina-registration-30561845302

The purpose of the Meet with Series events at JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners such as big pharma or other investment corporations, through one-on-one meetings.

On March 16th, Illumina’s Director of Business Development, Stacie Young and Director of Corporate and Venture Development, Andrew Summers will give an overview presentation about the company's key areas of interest. Following the presentation, you’ll have the opportunity to introduce yourself to Stacie and Andrew during the networking lunch. And finally, for those companies who apply online are approved, one-on-one meetings with Illumina provides an intimate forum to discuss your company.

Illumina is looking for potential partnerships with companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal wellness. Their goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago.

Some areas for potential partnership include, but are not limited to:

  • Genomics Research
  • Oncology
  • Reproductive Health
  • Agrigenomics
  • Complex Disease
  • Microbial Genomics
  • Informatics, Genomics Analysis



Agenda:
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on February 12th.


Illumina Participating Representatives:
Andrew Summers | Director, Corporate & Venture Development, Illumina
Since joining Illumina in 2011, Andrew has been involved in driving business development, acquisitions, corporate venture capital investments, and other partnering activities to support corporate strategy. Prior to Illumina, Andrew actively led financings for life science and technology companies at a venture capital firm and served as a board observer to several portfolio companies. He has been involved in over $1 billion in acquisitions and venture capital financings and has broad experience working closely with entrepreneurs, investors, and boards of directors to develop strategy and create value. Previously, Andrew held roles in investment banking and consulting with a focus on emerging technology companies. Andrew holds a BA from Washington State University and a MBA from the UCLA Anderson School of Management.
Connect with Andrew: Connect on LinkedIn


Illumina Participating Representatives:
Stacie Young | Director, Business Development, Illumina
Stacie leads partnering efforts to support product development and commercialization strategies for Illumina’s Reproductive and Genetic Health Business Unit. In addition, she manages relationships with such partners to evaluate and implement new business opportunities.

Stacie joined Illumina in 2013 as part of the effort to introduce Illumina’s Next Generation Sequencing (NGS) technology into clinical markets. With a primary focus on external activities, she also sponsors internal initiatives to define and operationalize business processes supporting this customer segment. Prior to Illumina, Stacie spent 9 years at Alere Inc, (formerly Biosite Inc), in new product planning and business development for Women’s Health and Oncology IVD products. Her training in genetic analysis came from 3 years at Incyte Genomics and 2 years in Stephen Hauser’s Neuroimmunology laboratory at the University of California, San Francisco.

Stacie holds a Bachelor’s degree in Biology from the University of California, Santa Barbara and a Master’s in Public Health from Columbia University in New York City.
Connect with Stacie: Connect on LinkedIn


Fees:
Presentation & Lunch
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until March 15th, 2017 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on February 12, 2017. Your application will be reviewed and you will be notified of acceptance by March 2, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.


About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.


Location:
JLABS
3210 Merryfield Row
San Diego, CA

Share